Oric Pharmaceuticals Launches New 2026 ATM Share Program

Oric Pharmaceuticals ( (ORIC) ) just unveiled an update.

On May 6, 2021, ORIC Pharmaceuticals, Inc. entered into an Open Market Sale Agreement with Jefferies LLC to sell common shares through an at-the-market offering program, using Jefferies as sales agent under an effective shelf registration filed on March 11, 2024. Under a 2024 prospectus supplement tied to this agreement, the company sold 13,478,432 shares for gross proceeds of about $139.7 million as of February 23, 2026, and on February 26, 2026, it transitioned to a new 2026 prospectus supplement for up to $200 million in additional share sales, with no further issuances to occur under the 2024 supplement.

The most recent analyst rating on (ORIC) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Oric Pharmaceuticals stock, see the ORIC Stock Forecast page.

Spark’s Take on ORIC Stock

According to Spark, TipRanks’ AI Analyst, ORIC is a Neutral.

Overall score is held back primarily by the pre-revenue model with substantial and slightly worsening losses and heavy cash burn, partially offset by a strong, low-debt balance sheet. Technical signals are mixed (near-term strength but negative MACD and intermediate trend pressure), while valuation is constrained by negative earnings and no dividend. Recent positive clinical-trial corporate updates provide a supportive catalyst offset.

To see Spark’s full report on ORIC stock, click here.

More about Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc. is a biopharmaceutical company that operates in the life sciences industry and is listed on public markets. The company issues common stock to fund its operations and growth initiatives, using registered shelf offerings and at-the-market equity programs to access capital over time.

Average Trading Volume: 1,493,661

Technical Sentiment Signal: Buy

Current Market Cap: $1.05B

For detailed information about ORIC stock, go to TipRanks’ Stock Analysis page.